Open AccessConsequenses for HRT following the HERS II and WHI reports: The primum non nocere is important, but translation into quo vadis is even more essential
Author(s) -
Skouby Sven O.
Publication year - 2002
Publication title -
acta obstetricia et gynecologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.401
H-Index - 102
eISSN - 1600-0412
pISSN - 0001-6349
DOI - 10.1034/j.1600-0412.2002.810901.x
Subject(s) - medicine , primum non nocere , progestin , hormone replacement therapy (female to male) , placebo , clinical trial , estrogen , family medicine , gynecology , alternative medicine , intensive care medicine , testosterone (patch) , pathology
In the Nordic countries the prevalence of hormonal replacement therapy (HRT) use in women from 50 to 70 years of age is slightly above 30% evaluated by sales figures and with some variation between the five countries. The premise for this commentary is to discuss the best clinical practice when prescribing HRT to post menopausal women following the publication of the most recent evidence from two well conducted randomized placebo controlled trials, namely the Heart and Estrogen/Progestin Replacement Study II (HERS II) and the Women's Health Initiative study (WHI ).